Clinical Trial Update: A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I [Phase 2]

View source ↗

Summary

Phase 2 study evaluating long-term safety and efficacy of VX-670 in patients with Myotonic Dystrophy Type 1; the trial is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myotonic Dystrophy Type

Drugs mentioned

• VX-670

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Myotonic Dystrophy Type 1 (DM1) | Phase 2 | Status: ENROLLING_BY_INVITATION